Choncept

Choncept is a pre-clinical stage biotechnology company focused on the development of precision therapeutics that remodel the cellular glycocalyx. Spun out of the University of California, San Diego, the company leverages a proprietary platform to engineer glycosaminoglycans (GAGs) on the cell surface, which are often dysregulated in cancer and inflammation. Choncept's approach involves using specialized enzymes and chemical biology tools to selectively modify these sugar structures to disrupt disease-promoting signaling pathways. The company's primary focus is on oncology, where it aims to enhance the efficacy of existing treatments and develop novel monotherapies by targeting the tumor microenvironment. By precision-targeting the glycocalyx, Choncept seeks to unlock new therapeutic possibilities for hard-to-treat solid tumors.